View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
GMALL-EVOLVE - ALL Blinatumomab (week 13,29,43 Imatinib), 18 - 65 years, Ph/BCR-ABL+
Protocol-ID: 3124 V1.0 (Mini), GMALL-EVOLVE-ALL Blina (w13,29,43 IMAT), 18 - 65, Ph/BCR-ABL+Study protocol, available to authorized participants only.
Indication(s)
- Acute Lymphoblastic Leukaemia; ICD-10 C91.0-
BCR-ABL positive
Links
- Studie GMALL08_2013, Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL Patients [clinicaltrials.gov]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. |
Valid since: 24.03.2026